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Several lines of evidence suggest that L-type Ca :~ channels (I ,4-dihydropyridin¢ receptors) are modulated by GTP-binding proteins. We have further 
examined this interaction by measuring the effect of 1,4-dihydropyridlnes on GTPase activity in brain membranes. Dihydropyridine agonists 
significantly increased GTPase, reflected by an increase in the maximal rate of GTP hydrolysis, without affecting the affinity for GTP or the binding 
ofa non-hydrolysable analogue of GTP. The stimulating effect on GTPase was abolished by antisera raised against Go" but not G~ct. L-type Ca :~ 
channels may act as endogenous GTPas¢ activating proteins (GAPs) to stimulate GTP hydrolysis by Go. 
1,4-Dihydropyridine; Calcium channel; G-protein; GTPase; Go; Baelofen 
1. INTRODUCTION 
Interactions between voltage-dependent neuronal 
Ca :÷ channels and various neurotransmitter r ceptors 
are mediated via regulatory GTP-binding proteins (G- 
pro,~eins) which are sensitive to pertussis toxin [1-3]. 
Recent studies have demonstrated that a likely candi- 
date for the subtype of G-protein involved is Go since 
reconstitution f purified Go into cells pretreated with 
pertussis toxin restores the inhibition of Ca -~" currents 
induced by receptor activation [4-7]. In addition, drug- 
induced inhibition of Ca "~* currents is attenuated by 
anti-Go antibodies [5,8,9] and antisense oligonucleo- 
tides complementary to the mRNA of the g-subunit of 
Go [10]. In the latter case, the Ca a* current involved was 
identified as an L-type current [10] although non-L-type 
currents are also inhibited by neurotransmitters [2].The 
interaction of 1,4-dihydropyridines with L-type Ca 2+ 
channels i also modulated by a G-protein. This hypoth- 
esis was based initially on ¢lectrophysiologieal studies 
where activation of pertussis toxin-sensitive G-proteins 
enhanced the potentiation ofCa -~* currents produced by 
CorrenTandetzce ad,'re.~s: M.I. Sweeney, Department of Pharmacol- 
ogy, Royal Free Hospital School of Medicine, Rowland Hill St., 
London NW3 2PF, UK. Fax: (44) (71) 794 6854. 
Abbrevfations: GTP, guanosine triphosphate; GTP2'$, guanosine 5'- 
O-3-thiotriphosphatc; p['NH]ppA, adenosine 5'-[flq'-imido] tri- 
phosphate; 202-791, 2,6-dimethyl-3-nhro-5-isopropylcarboxylat¢-4- 
(2,1,3-benzozadiazo-4-yl)-i,4-dihydropyridine; Bay K 8644, 2,6-di- 
methyl-3-nitro-5.methylearboxylate-4-(2-tri-fluoromethylphenyl). 
1,4-dihydropyridine; PN 200-110, 2,6-dimethyl-3-isopropyi-earboxyl- 
ate-5-carbomethoxy-4-(2,1,3-benzoxadiazo-4-yl)-l,4-dihydropyrid- 
ine; 4-chloro.nifedipine, 2,6-dimethyl-3,5-dicarbomethoxy-4.(4-chlo- 
rophenyl)-l,4-dihydropyridine. 
dihydropyridine agonists [11]. In binding experiments, 
GTP analogues increase the affinity of dihydropyridine 
agonist binding to membranes prepared from frontal 
cortex [12] and skeletal muscle [13]. 
G-proteins contain an intrinsic GTPase activity 
which hydrolyses GTP, bound to the activated state of 
the 0~-subunit, to GDP thereby inactivating and recy- 
cling the O-protein (reviewed in [14]). If an agonist- 
bound neurotransmitter r ceptor interacts with a G- 
protein, then an increase in GTPase usually occurs. In 
the present study we have demonstrated a significant 
stimulation of a high affinity GTPase activity by (-)- 
baclofen, an agonist at GABAa receptors. In addition, 
a profound stimulation of GTPase was prodnced by 
1,4-dihydropyridines, particularly agonists, that act on 
effector L-type Ca 2+ channels. This effect was reduced 
by pretreatment with antisera raised against Gog. Thus, 
this may represent a novel mechanism by which L-type 
Ca ~-~ channels terminate their interaction with Go. 
2. EXPERIMENTAL 
2.1. Preparat,'on ofmembrane~' 
The frontal cortex of adult male Wistar rats (BK Universal, Hall, 
UK) wa~ homogenized (8 strokes) in ice.cold 10 mM Tris-HCI/I mM 
EDTA, pH 7.4 (buffer A) containing the following protease inhibitor 
cocktail: 5 mM beazamidlne, 5 mM dithiothreitol, 100/.tM ehlorpro- 
mazine, 50 ~uM leupeptin, and aprotinin (0.25 trypsin inhibitor U/ml). 
Following eentrifugation at 1,000 x g for l0 min at 4"C, the superna- 
tam was centrifuged at 40,000 × g for 10 rain at 4°C. The resulting 
membrane pellet was washed and resaspended in the homogenizing 
buffer (final concentration 1 mg protein/ml). 
2.2. GTPase assays 
20/.~I of membrane suspension or de-ionized water were aaded in 
triplicate to 30/~1 drug(s) and 50/.d of GTPase assay mix containing 
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approximately 100,000 cpm of [ynP]GTP (NEN), GTPas¢ activity 
was quantitated by measuring [~"P]GTP hydrolysis at 370C for 10 min 
¢ssentlally as de~ribod previously [15] except hat 20 mM Tris-HCl 
and 1 mM crcatine phosphate were used, and p[NH]ppA was omitted. 
[3:PIGTP hydrolysis was terminated by the removal to ice and addition 
of 900 ,ul of 2% charcoal in 20 mM phosphoric acid containing :~'ro 
ethanol. Aliquots (200 #1) of the supernatant resulting from centrifa- 
gation at 1,500 x g ibr i0 miu were cou,ited for ~P content in a liquid 
scintillation counter, 111 some experiments, membranes were pre- 
treated for I h at 30°C either with non-immune serum or anti-G- 
p,'owin ~ntisera (diluted 1:50) before [~-'P]GTP hydrolysis was as- 
sessed, Antisera used were OCI, 0C2 and ONI, directed against 
peptide ~equences in Gjz or the anti-G~a ntiserum AS7. When OC2 
and AS7 were used, all sera were pre.incubated ither with the peptides 
used for immunization (ANNLRGCGLY or KENLKDCGLF, re- 
spectively; 2 mg/ml) or vehicle (50 mM NaH.PO4, pH 6) for 1 h at 
30°C. Vm.~ and KM for OTPase were determined using the Line- 
weaver-Burke analysis with GTP concentratlons of 0.02, 0.2, 0.4, 0.8 
and 2/~M, 
2.3. [~SSfGTPZS hh~di.g experm~ents 
These were performed for 20 min at room temperature according 
to the method of Avissar et al. [l 6] with minor modifications. Mem- 
brane suspensions (0.5 mg protein/ml in buffer A, 100/~l aliquots) were 
added in triplicate to 1.5 ml microfuge tubes containing 10/.tl ofdrug, 
and 30/al of buffer A containing l0 mM MgCI: and l0 nM GTPF[a~S] 
(NEN) (final concentrations). Non.specific binding was assessed using 
GTP (500/zM) or unlabelled GTPTS (10/JM). Binding was terminated 
by diluting with 3 vols. of ice-cold 100/.tM GTP in buffer A, and 
centrifuging immediately at12,000 xg for 5 rain at 4°C. The pellet was 
washed 3 times, solubiiized, and then counted for bound "~S in a 
scintillation counter, B,,~ and fi'D were determined using the 
Scatehard analysis with frcc GTPT['S] concelurations o1"0.3, l, 3 and 
l0 nM, 
All GTPase and binding experiments with dihydropyridines were 
performed under infra.red lighting. 
3. RESULTS 
Incubation of rat frontal cortical membranes with the 
GABAn receptor agonist (-)-baclofen (1-30/zM) pro- 
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Fig. 2, Effect of(-)-baclofen and dihydropyrldin¢ agonists on GTPa~ 
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"P < 0.05, analysis of variance compatv.d to the increase in V~, with 
baclofen (BAC) or (+)-202-791 ((+)-202) alone (. = 7) (B) or com- 
pared to conlrol B,,~, (n = 6) (D). 
duced a dose-dependent increase in the hydrolysis of 
[nP]GTP (Fig. I). The effect of baclofen was maximal 
at 10 !.~M, and was due to stimulation of a high-affinity 
GTPase since no enhancement of  GTPase was observed 
in the presence of 10/zM GTP?'S, a non-hydrolysable 
analogue of GTP which binds irreversibly to the high- 
affinity guanine nucleotide binding site on G-proteins 
(Fig. 1). When Lineweaver-Burke analyses were per- 
formed (Fig. 2A), 10 ~tM baclofen had no effect on the 
apparent affinity (KM) Of OTPase for GTP (111 + 16% 
of control, P = 0.9, n = 7) but produced a profound 
(41 + 12%) increase in the maximal rate of GTP hydrol- 
ysis (V,~)  (Fig. 2B). Dihydropyridines also stimulated 
a high-affinity GTPase activity. The agonist (+)-202- 
791 (0.33-10/zM) produced an 18-96% increase in V,~,~ 
with no significant effect on KM (Table 1), and similar 
results were obtained using the agonist (+_)-Bay K 8644, 
and to a lesser extent the antagonists (-)-202-791 and 
(+)-PN 200-110 (isradipin¢) (Table 1). When dihy- 
dropyridine concentrations were express~ relative to 
the concentrations required to produce half maximal 
binding to cardiac membranes (KD's taken from [17]), 
it was observed that agonist enantiomers produced el- 
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Table [ 
Effect of dihydropyridine agonists and antagonists on K M and Vn~  of 
GTPase in frontal cortical membranes 
K.~ ~uM) V.,,,, (pmol/mg 
proteln/rain) 
Agonists 
Control 0.59 ± 0.08 (100) 176.3 :t 41.5 (100) 
(+)-202-791, 0.33 gM 0,56 -+ 0,07 (95) 208,0 --. 62.0 (118) 
(+)-202-791, 1 ltM 0,62 + 0.13 (104) 261,2 + 50.7 (148)'" 
(+).202-791, 10/.tM 0,47 ± 0.06 (79) 345.6 + 70,1 (196)" 
Control 1,02 ± 0,37 (100) 231,2 __. 45.1 (100) 
(_+)-BayK8644,0,1/~M 0,97_+0,26 (95) 307.7 ~- 49.4 (133)' 
(+-)-Bay K 8644, 1 ~tM 0,96 _'2 0.21 (94) 396,1 _+ 46,8 (174)'" 
(+)-Bay K 8644, 10/JM 0,75 ± 0,16 (74) 416.0 + 77.5 (180)" 
Antagonists 
Control 0,59 --. 0.08 (100) 176,3 ± 41,5 (100) 
(-)-202-791, 0.33/.tM 0,53 + 0.07 (89) 181.6 + 54.5 (103) 
(-).202-791, 1,0/.tM 0.81 ± 0,33 (137) 248.2 ± 59,0 (141)" 
(-)-202-791, 10.0 t im 0,47 + 0,07 (80) 267,9 ± 74,0 (152)" 
Control 0,55 -2_ 0.10 (100) 144.5 ± 28,4 (100) 
(+)-PN200-110,0.1/.tM 0.52:t:0,09 (95) 185,0 _+43,9(128) 
(+)-PN 200-110, 1 btM 0.56 _ 0,09 (102) 204,5 ± 57,7 (141) 
(+)-PN 200--110, 10,uM 0,49 ± 0,10 (89) 270,8 _ 55,1 (187)" 
The Kr~ and Vm.~ value5 were determined using the Lineweaver-Burk¢ 
analysis described in Fig. 2. All resression lines showed regression 
coefficients of r > 0,98 (P < 0,001, n = 6--12), Values in parentheses 
are the K~: or V,..~ values expressed as percentages of controls (0,4% 
ethanol). 'P  < 0,05, "'P < 0.01, ' "P  < 0,001, paired t-test, compared 
to controls, 
feets at concentrations which were 10-20-times their KD 
for binding (96 nM for (+)-202-791, 6 nM for Bay K 
8644), whereas the antagonists only produced effects at 
> 103-times their KD (0.23 nM and 0.034 nM, respec- 
tively, for (-)-202-791 (and (+)-PN 200-110). A 4- 
chloro-derivative of nifedipine, which is structurally 
similar to 1,4-dihydropyridines but is 10,000-fold less 
potent at binding to dihydropyridine r ceptors [I 8], and 
omega-eonotoxin GVIA, which inhibits N-type Ca 2+ 
channels [3], had no effect on GTPase, the Vm..,~ being 
105 + 18% and 102 + 11% of controls, respectively, in
the presence of 10/.tM of these agents (P > 0.55, n = 4- 
6). 
When 10 #M baclofen and 1 lzM (+)-202-791 were 
co-incubated with the membranes, an additive increase 
in Vm,~ of GTPase activity was observed (Fig. 2B). This 
suggests either that the two drugs interact with different 
G-proteins and the net effect is simply an additive stim- 
ulation of GTPase, or that the same G-protein whose 
rate of GDP-GTP exchange is stimulated by activation 
of the agonist-bound receptor [14] may be further mod- 
ulated by interaction with a dihydropyridine r ceptor. 
In order to distinguish between effects on GTP hydrol- 
ysis and nucleotide exchange, the effect of bac!ofen and 
Bay K 8644 on the binding of [~SS]GTPTS to frontal 
conical membranes was determined. When Scatchard 
analyses were performed (Fig. 2C), 10 ,uM Bay K 8644 
had no significant effect on the apparent KD for binding 
[3~S]GTPTS (11.1 nM in control conditions and 14.2 nM 
in the presence of Bay K 8644), and there was no effect 
on the maximal number of binding sites (B,~.,~) (Fig. 
2D). In contrast, 10,uM baclofen increased the Bmu x by 
36 + 5% (Fig. 2D) and increased the binding affinity to 
8.9 nM, corresponding to a 31 __. 2% increase in affinity 
(P < 0.03, paired t-test, n = 6). 
In order to identify the G-protein(s) whose GTPase 
activity was stimulated by baclofen and dihydropyri- 
dines, frontal cortical membranes were treated in vitro 
with anti-G-protein antibodies for 1 h at 30=C. The 
specific antisera used were OCI or OC2 and ONI, 
raised against C- and N-terminal peptides, respectively, 
of Go¢~, and AS7, which is directed against a C-terminal 
peptide sequence from G~ [19]. The stimulatory effect 
of dihydropyridine agonists on GTPas¢ was completely 
eliminated by pretreatment of membranes with the anti- 
GoCZ antisera. Thus, the enhancement of GTPase by 3.3 
/.tM (+)-202-791 was attenuated by both OCI (Fig. 3A) 
and ONI (Fig. 3B), and 10//M (+_)-Bay K 8644-induced 
stilrmlation was inhibited by OC2 (Fig. 3A). Dihy- 
dropyridine-induced stimulation of GTPase was not 
significantly affected by the anti-Gi~¢ antiserum, AS7 
(Fig. 3C). In contrask pretreatment with AS7 produced 
a complete inhibition of the stimulation of GTPase by 
10/~M baclofen (Fig. 3C), while anti-Go antisera, OC2 
(Fig. 3A) and ONI (Fig. 3B), produced only a partial 
(45 + 1% and 77 + 12%, respectively) reduction in the 
effect of baclofen. Pre-incubation (1 h, 30°C) of OC2 
(Fig. 3A) and AS7 (Fig. 3C) with the respective peptides 
used for immunization (2mg/ml) significantly reversed 
the effects of the antisera on inhibiting baelofen- or Bay 
K 8644-stimulated GTPase. In all cases, control mem- 
branes were treated at 30°C with non-immune serum, 
and anti G-protein antibodies had no effect on basal 
GTPase activity (see legend to Fig. 3). 
4. DISCUSSION 
We have demonstrated that binding of ligands to 
dihydropyridine r ceptors, located on the al subunit of 
L-type Ca 2. channels [20-22], produces an increase in 
the activity of a high-affinity GTPase (KM < 1 /aM). 
This stimulation appears to be due to an increase in the 
rate of GTP hydrolysis, and not nucleotide xchange, 
resulting from Go interacting directly with the L-type 
Ca 2÷ channel in a state which is favored by dihy- 
dropyridine agonist binding, since agonist dihy- 
dropyridines were more effective than antagonists rela- 
tive to their Kt~ for binding to the dihydropyridine r - 
ceptor. Both the C- and N-terminal regions of Go~ may 
be important in this modulation as the stimulation of 
GTPase by ago:~.ist dihydropyridines was completely 
eliminated by pretreatment of membranes with specific 
antisera raised against either the C- or N-terminal re- 
gions of Gocz. Previously, both antisera have demon- 
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Fi6, 3. Effect of incubation of frontal cortical membranes with anti- 
Go" antisera, OCI or OC2 (A) and ONI (B), anti-G~ antiserum AS7 
(C), or non-immune serum on GTPase activity stimulated by (-)- 
baclofen and dihydropyridlne agonists. Values are means + S.E.M. of 
the % increase above basal GTPase. Values for basal GTPase activity 
were (pmol/mg protein/rain): 51.5 ± 4.2, 59.5 + 3.0, 58.6 ± 5.1, and 
55.9 ± 6.8 for non-immune serum, non-immune serum plus G,,r~ pep- 
tide, OC 1/OC2 and OC2 plus Gog peptide, respectively (A); 46. I + 5.4 
and 46.3 +- 5.7 for non-immune serum and ONI, respectively (B); and 
43.0 _+ 1.3, 49.5 + 2.3, 43.1 ± 2.1, and 46.2 Z 1.1 for non-immune 
serum, non-immune serum plus GLcz peptide, AS7 and AS7 plus G~ 
peptide, respectively (C). ' P< 0.05, "'P < 0.01, paired t-test, com- 
pared to drug-stimulated GTPase in membranes treated with non- 
immune serum (n --5-8). 
strated a high specificity and selectivity to recognize a
39 kDa protein corresponding to Go~ while not cross- 
reacting with G~ [19]. Our results have been extended by 
showing that Bay K 8644 stimulates GTPase in mem- 
branes prepared from cultured cerebellar granule neu- 
rons, and that this effect is prevented by pretreatment 
of the cells with pertussis toxin (M. Silver, M.1.S. and 
A.C.D., manuscript in preparation). We are currently 
examining the effect of dihydropyridines on GTPase in 
a purified reconstituted membrane system. 
Neurotransmitters inhibit voltage-dependent Ca"-+ 
channels in neurons and secretory cells via Go ([4,8-10]; 
see Introduction). The Ca ~-+ channel type which is mod- 
ulated appears to be N-type in some neurons because 
of its sensitivity to omega-conotoxin, and because dihy- 
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dropyridine-agonist-enhanced tail currents do not dis- 
play this modulation [2,231. However, there is also good 
evidence that L-type currents which are dihydropyrid- 
ine-sensitive can also be modulated by Go [3,10,24]. In 
the experiments described here, we have not addressed 
the interaction of Go with N-type Ca 2+ channels because 
of the lack of state-dependent ligands for these chan- 
nels, and omega-conotoxin had no effect on GTPase 
activity. 
Stimulation of GTPase by the dihydropyridines was 
not affected by AS7 which recognizes Gi [19], strongly 
suggesting that L-type Ca 2+ channels do not interact 
directly with Gi. Baclofen-induced stimulation of 
GTPase was reduced substantially by anti-G~0~ antisera, 
but also was reduced partially by anti-Go0~ antisera, 
suggesting that GABAa receptors interact with Gi, and 
to a lesser extent with Go, to stimulate a high affinity 
GTPase. It has been shown previously that a baclofen- 
mediated increase in GTPase was blocked by pretreat- 
ment with pertussis toxin [25]. Activation of G~ by ba- 
clofen would lead to an inhibition of adenylate cyclase 
(reviewed in [25]), while recent studies in our laboratory 
[9] have indicated that the baclo/~n-mediated inhibition 
of Ca -~÷ currents in dorsal root ganglion neurons is me- 
diated via Go. 
The data described here suggest that the L-type Ca -'+ 
channel may act as a GTPase activating protein (GAP) 
when in the dihydropyridine-agonist-bound state. This 
may represent a mechanism whereby the channel, hav- 
ing interacted with the G-protein which modulates its 
gating kinetics [26], limits the temporal effectiveness of
the modulating signal. Thus, the life-time of the chan- 
nel/Go~ complex will be reduced because the intrinsic 
GTPase activity of cto has been increased. Dihy- 
dropyridine agonists bind preferentially to the resting 
state of the channel [27], and their binding and actions 
are modified by subunit composition [28]. Their ability 
to enhance GTPase may indicate that Gjz also interacts 
with the Ca ~-+ channel in the same state. This hypothesis 
could explain why dihydropyridine agonists increased 
the binding of [3H]baelofen to GABAB receptors in rat 
cerebral cortical membranes [29], i.e. by increasing the 
proportion of  G-proteins in the ground state. From 
studies on Gk activation of the cardiac K + currents 
(lktm)) [30] it has been observed that the k,~,, determined 
from the rate of decay oflk(M) is over 100 min -~, whereas 
this value is about 2 rain -I in purified preparations of 
Gi or Go [14,31]. A similar mechanism, where the effec- 
tor (phosphodiesterase) accelerates the normally slow 
rate of GTP hydrolysis by a heterotrimeri¢ G-protein 
(transducin) has recently been proposed [32,33]. In ad- 
dition, there exists a family of GAPs which stimulate the 
very slow endogenous GTP hydrolysis by small Q.pro- 
teins, including p21 "~ (reviewed in [14]), and may also 
act as effectors for this G-protein [34]. Our results indi- 
cate that interaction with effector (in this case L-type 
Ca ~-÷ channels) may represent a widespread mechanism 
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by which intrinsic G-protein GTPase  activities are en- 
hanced. 
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